## CADTH **PCODR** PAN-CANADIAN ONCOLOGY DRUG REVIEW

## **PROVINCIAL FUNDING SUMMARY**

Irinotecan Liposome (Onivyde) for Metastatic Pancreatic Cancer (pCODR 10107)

## pERC Recommendation: Recommends with conditions For further details, please see <u>pERC Final Recommendation</u>

## Notification to Implement Issued by pCODR: January 22, 2018

This information is current as of August 1, 2019.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs for the most recent funding criteria and program eligibility.

PROVINCE	FUNDING STATUS	FUNDING DATE	FUNDING CRITERIA
BC	Negotiations were closed as an agreement could not be reached		
AB	Negotiations were closed as an agreement could not be reached		
SK	Negotiations were closed as an agreement could not be reached		
MB	Negotiations were closed as an agreement could not be reached		
ON	Negotiations were closed as an agreement could not be reached		
NS	Negotiations were closed as an agreement could not be reached		
NB	Negotiations were closed as an agreement could not be reached		
NL	Negotiations were closed as an agreement could not be reached		

Provincial Funding Summary - Irinotecan Liposome (Onivyde) for Metastatic Pancreatic Cancer (pCODR 10107) Date Posted: August 12, 2019 © 2019 pCODR | PAN-CANADIAN ONCOLOGY DRUG REVIEW

